Plaque vulnerability at non-culprit lesions in obese patients with coronary artery disease: Frequency-domain optical coherence tomography analysis

European Journal of Preventive Cardiology

Volumn 22, Issue 10, 2015, Pages 1331-1339

  Kataoka, Yu ^a   Hammadah, Muhammad ^b   Puri, Rishi ^b   Duggal, Bhanu ^b   Uno, Kiyoko ^b   Kapadia, Samir R ^b   Tuzcu, E Murat ^b   Nissen, Steven E ^b   Nicholls, Stephen J ^a  

^a SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Imaging; Obesity; Plaque

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; LIPID;

ADULT; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; BODY MASS; CALCIFICATION; CARDIAC PATIENT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE PREDISPOSITION; FEMALE; FREQUENCY DOMAIN OPTICAL COHERENCE TOMOGRAPHY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IMAGING SOFTWARE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OBESITY; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RUPTURE; THROMBUS; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; COMPLICATION; CORONARY BLOOD VESSEL; FIBROSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR;

AGED; BIOMARKERS; BODY MASS INDEX; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; CORONARY VESSELS; FEMALE; FIBROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PLAQUE, ATHEROSCLEROTIC; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84944885467     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487315598711     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention National Center for Health Statistics. Obesity and overweight, http://www.cdc.gov/nchs/fastats/obesity-overweight.htm.
2. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303:235-241.
3. Yach D, Stuckler D and Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 2006;12:62-66.
4. Klein S, Burke LE, Bray GA, et al. American Heart Association Council on Nutrition, Physical Activity, and Metabolism Clinical implications of obesity with specific focus on cardiovascular disease: A statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation. Circulation 2004;110:2952-2967.
5. Balkau B, Deanfield JE, Desprees JP, et al. International Day for the Evaluation of Abdominal Obesity (IDEA): A study of waist circumference, cardiovascular disease, and diabetes mellitus in 168, 000 primary care patients in 63 countries. Circulation 2007;116:1942-1951.
6. Despres JP and Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881-887.
7. Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART study investigators Obesity and the risk of myocardial infarction in 27, 000 participants from 52 countries: A case-control study. Lancet 2005;366:1640-1649.
8. Hubert HB, Fenileib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-977.
9. Berg AH and Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-949.
10. Yu Y-H and Ginsberg HN. Adipocyte signaling and lipid homeostasis: Sequelae of insulin-resistant adipose tissue. Circ Res 2005;96:1042-1052.
11. Ferroni P, Basili S, Falco A, et al. Inflammation, insulin resistance, and obesity. Curr Atheroscler Rep 2004;6:424-431.
12. Lindberg S, Jensen JS, Bjerre M, et al. Adiponectin, type 2 diabetes and cardiovascular risk. Eur J Prev Cardiol 2015;22:276-283.
13. Van Berendoncks AM, Stensvold D, Garnier A, et al. Disturbed adiponectin - AMPK system in skeletal muscle of patients with metabolic syndrome. Eur J Prev Cardiol 2015;22:203-205.
14. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). Am J Cardiol 2006;97:1553-1557.
15. Kojima S, Kojima S, Maruyoshi H, et al. Hypercholesterolemia and hypoadiponectinemia are associated with necrotic core-rich coronary plaque. Int J Cardiol 2011;147:371-376.
16. Kunita E, Yamamoto H, Kitagawa T, et al. Association between plasma high-molecular-weight adiponectin and coronary plaque characteristics assessed by computed tomography angiography in conditions of visceral adipose accumulation. Circ J 2012;76:1687-1696.
17. Kang SJ, Mintz GS, Witzenbichler B, et al. Effect of obesity on coronary atherosclerosis and outcomes of percutaneous coronary intervention: Grayscale and virtual histology intravascular ultrasound substudy of assessment of dual antiplatelet therapy with drug-eluting stents. Circ Cardiovasc Interv 2014;8:e001392.
18. Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science 1991;254:1178-1181.
19. Jang IK, Bouma BE, Kang DH, et al. Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: Comparison with intravascular ultrasound. J Am Coll Cardiol 2002;39:604-609.
20. Yun SH, Tearney GJ, Vakoc BJ, et al. Comprehensive volumetric optical microscopy in vivo. Nat Med 2006;12:1429-1433.
21. Finn AV, Nakano M, Narula J, et al. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010;30:1282-1292.
22. Falk E, Nakano M, Bentzon JF, et al. Update on acute coronary syndromes: The pathologists' view. Eur Heart J 2013;34:719-728.
23. Tearney GJ, Regar E, Akasaka T, et al. International Working Group for Intravascular Optical Coherence Tomography (IWG-IVOCT) Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: A report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol 2012;59:1058-1072.
24. Kitabata H, Tanaka A, Kubo T, et al. Relation of microchannel structure identified by optical coherence tomography to plaque vulnerability in patients with coronary artery disease. Am J Cardiol 2010;105:1673-1678.
25. Chen H, Montagnani M, Funahashi T, et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003;278:45021-45026.
26. Ouchi N, Ohishi M, Kihara S, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003;42:231-234.
27. Kobashi C, Urakaze M, Kishida M, et al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 2005;97:1245-1252.
28. Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004;109:2046-2049.
29. Lago F, Dieguez C, Gomez-Reino J, et al. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 2007;3:716-724.
30. Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial cell activation: Further evidence of adipokine-endothelial interaction. Circulation 2003;108:736-740.
31. Sawada T, Shite J, Shinke T, et al. Low plasma adiponectin levels are associated with presence of thin-cap fibroatheroma in men with stable coronary artery disease. Int J Cardiol 2010;142:250-256.
32. Choi HY, Kim S, Yang SJ, et al. Association of adiponectin, resistin, and vascular inflammation: Analysis with 18F-fluorodeoxyglucose positron emission tomography. Arterioscler Thromb Vasc Biol 2011;31:944-949.
33. Ohashi N, Yamamoto H, Horiguchi J, et al. Association between visceral adipose tissue area and coronary plaque morphology assessed by CT angiography. JACC Cardiovasc Imaging 2010;3:908-917.
34. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010;376:1670-1681.
35. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435.
36. Nissen SE, Nicholls SJ, Sipahi I, et al. ASTEROID investigators Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006;295:1556-1565.
37. Nissen SE, Tuzcu EM, Schoenhagen P, et al. REVERSAL investigators Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004;291:1071-1080.
38. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011;365:2078-2087.